Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors ; day:25 ; month:9 ; year:2017 ; pages:1-10
Oncology and Therapy ; (25.9.2017), 1-10
- Keyword
-
Krebs
Onkologie
- Creator
-
Shen, Lin
- Contributor
-
Sun, Yan
Xu, Jian-Ming
Linn, Carlos
Wang, Qiao
Yang, Li-Qiang
Qin, Shu-Kui
SpringerLink (Online service)
- DOI
-
10.1007/s40487-017-0052-4
- URN
-
urn:nbn:de:1111-201711223105
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shen, Lin
- Sun, Yan
- Xu, Jian-Ming
- Linn, Carlos
- Wang, Qiao
- Yang, Li-Qiang
- Qin, Shu-Kui
- SpringerLink (Online service)
Other Objects (12)
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
Positive solutions for one-dimensional third-order p-Laplacian boundary value problems
Regorafenib bei GIST : neuer Therapie-Standard bei Progress nach Imatinib und Sunitinib
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Economic Opportunities and Gender Equity: The Migration and Education Decisions of Young Women from Rural China
Bi-objective optimization for multi-modal transportation routing planning problem based on Pareto optimality
Learning Bayesian network structure based on the classification and regression tree
Dynamic Bayesian network modeling for intervention mechanism
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
Positive solutions for one-dimensional third-order p-Laplacian boundary value problems
Regorafenib bei GIST : neuer Therapie-Standard bei Progress nach Imatinib und Sunitinib
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Economic Opportunities and Gender Equity: The Migration and Education Decisions of Young Women from Rural China
Bi-objective optimization for multi-modal transportation routing planning problem based on Pareto optimality
Learning Bayesian network structure based on the classification and regression tree
Dynamic Bayesian network modeling for intervention mechanism
Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
Positive solutions for one-dimensional third-order p-Laplacian boundary value problems
Regorafenib bei GIST : neuer Therapie-Standard bei Progress nach Imatinib und Sunitinib
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
Economic Opportunities and Gender Equity: The Migration and Education Decisions of Young Women from Rural China
Bi-objective optimization for multi-modal transportation routing planning problem based on Pareto optimality
Learning Bayesian network structure based on the classification and regression tree